Sociedad Americana de Hirudoterapia

Anticoagulants in children with renal impairment: a narrative review

Review published in Seminars in Thrombosis and Hemostasis (2025)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewEnsayos clínicosDesarrollo de fármacosKiskaddon AL et al. · Seminars in thrombosis and hemostasis, 2025

Abstract

Venous thromboembolism is a common cause of morbidity and mortality in children with renal disease. To properly treat and prevent thromboembolism in this patient population, it is important to be familiar with the multitude of anticoagulant agents currently available. Many anticoagulant drugs undergo some extent of renal elimination. There are important considerations for the selection, dosing, and monitoring of anticoagulant drugs for patients with renal impairment due to various pharmacokinetic alterations that may occur. While there are data to help guide dosing and monitoring in adults, evidence regarding renal dose adjustment of many anticoagulant drugs in children are limited. For the clinician, anticoagulation management in children with renal impairment presents unique challenges. In addition to considering overall bleeding risk, the extent of renal impairment may vary by patient, making a one-size-fits-all approach to managing these patients difficult. These factors, combined with limited data, can make managing anticoagulation in children with renal impairment a challenge. Therefore, the focus of this review will be to describe the pharmacokinetics of the following anticoagulants in children with impaired renal function: unfractionated heparin, enoxaparin, dalteparin, rivaroxaban, apixaban, edoxaban, fondaparinux, bivalirudin, argatroban, dabigatran, and warfarin.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsHumansAnticoagulantsChildVenous ThromboembolismRenal Insufficiency

Resumen

Pediatric review covering anticoagulant dosing in renal impairment including bivalirudin, argatroban and direct thrombin inhibitor adjustments by GFR.

Por qué esto importa para la hirudoterapia

This review article describes the pharmacokinetics of multiple anticoagulant agents—including unfractionated heparin, enoxaparin, dalteparin, rivaroxaban, apixaban, edoxaban, fondaparinux, bivalirudin, argatroban, dabigatran, and warfarin—in children with renal impairment, addressing the challenges of dosing and monitoring in this population. The authors note that evidence regarding renal dose adjustment of many anticoagulant drugs in children is limited. The abstract does not mention leeches, hirudin derivation, or hirudotherapy, so no defensible connection to ASH's domain can be established from this article alone. The review provides broad pharmacological context but is not focused on any leech-related compound or therapy.

Citación

Anticoagulants in children with renal impairment: a narrative review.

Kiskaddon AL et al. · Seminars in thrombosis and hemostasis, 2025

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.